Comparative mortality outcomes in metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease subtypes in the United States.

ABSTRACT:

Background

In 2023, experts from the European and American regions proposed the concepts of steatotic liver disease (SLD) and metabolic dysfunction-associated steatotic liver disease (MASLD). MASLD was proposed as a replacement for nonalcoholic fatty liver disease (NAFLD). We compared the long-term outcomes of patients with MASLD, NAFLD, and various subtypes of SLD.

Methods

We conducted a retrospective study using the NHANESIII database. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause mortality and cause-specific mortality among patients with subtypes of SLD, MASLD, and NAFLD.

Results

During a follow-up period of 31 years (median 25 years), the adjusted risks of all-cause death for patients wit

SUBMITTER: Zhang P 

PROVIDER: S-EPMC12578175 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature